Schrodinger Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
(b) Director and Officer Trading Arrangements
A significant portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or our other securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.
Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
The following table describes, for the fourth quarter of 2024, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a "non-Rule 10b5-1 trading arrangement" (as defined in Item 408(c) of Regulation S-K):
| Name and Title | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Shares of Common Stock |
|---|---|---|---|---|---|
| Robert Abel Executive Vice President, Chief Scientific Officer, Platform | Adoption(November 26, 2024) | Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares | Sale | Until December 31, 2025, or such earlier date upon which all transactions are completed or expire without execution | Up to 107,605 shares |
| Karen Akinsanya, President of R&D, Therapeutics | Adoption(December 17, 2024) | Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares | Sale | Until December 31, 2025, or such earlier date upon which all transactions are completed or expire without execution | Up to 121,178 shares |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.